IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3445 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (435 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed2386    
    Printed38    
    Emailed2    
    PDF Downloaded126    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2015  |  Volume : 81  |  Issue : 4  |  Page : 427-429

The effects of normobaric oxygen therapy on patients with periorbital darkening: An open, uncontrolled trial


1 Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Department of Dermatology, El Haud El Marsoud Hospital, Cairo, Egypt

Date of Web Publication3-Jul-2015

Correspondence Address:
Assoc. Prof. Dina M Kadry
Associate Professor of Dermatology, Faculty of Medicine, Cairo University, 13/2 Zahraa Street Maadi, Cairo
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.159946

Rights and Permissions



How to cite this article:
Mostafa WZ, Kadry DM, Mohamed EF. The effects of normobaric oxygen therapy on patients with periorbital darkening: An open, uncontrolled trial. Indian J Dermatol Venereol Leprol 2015;81:427-9

How to cite this URL:
Mostafa WZ, Kadry DM, Mohamed EF. The effects of normobaric oxygen therapy on patients with periorbital darkening: An open, uncontrolled trial. Indian J Dermatol Venereol Leprol [serial online] 2015 [cited 2019 Oct 20];81:427-9. Available from: http://www.ijdvl.com/text.asp?2015/81/4/427/159946


Sir,

Periorbital darkening is a condition with a complex etiology, including dermal melanosis, post-inflammatory hemodynamic congestion and skin laxity. Therefore a combination treatment approach has been suggested. [1] We found no previous reports of the use of oxygen in the treatment of periorbital darkening.

Thirty-five patients complaining of periorbital darkening, attending the dermatology outpatient clinic at Kasr Al ainy hospital, Cairo University, were included in this study. The study was approved by the institutional dermatology research ethical committee. Detailed personal and medical history of patients was obtained.

Before treatment, patients were graded clinically for pigmentation as mild, moderate and severe, for presence or absence of textural changes and dermoscopically for the different dermoscopic patterns of pigmentation, and presence or absence of erythema and telangiectasia. Details of the clinical, demographic and dermoscopic manifestations of periorbital darkening have been previously described and serve as 'pretreatment'. [2]

Oxygen was administered via a nasal cannula at a rate of 1 litre/min, for 1 hour twice weekly for 3 weeks. Multiple clinical and dermoscopic photographs of the periorbital area were obtained before and after therapy.

Following treatment, evaluation of the pre- and post-treatment clinical and dermoscopic photographs of patients was made by two independent observers. Clinical improvement including color lightening and/or reduction in the size of the affected area were assessed using a per patient relative improvement score that was graded such that a difference of 0 was recorded as no change, up to 25% as fair, >25-50% as good, >50-75% as very good and >75% as excellent. Dermoscopic evaluation included change in erythema and/or telangiectasia (when present) using the following grading system: decreased, increased and no change.

A final evaluation of the periorbital area was performed by three independent evaluators (one additional evaluator was external to the study), and an average overall improvement score was obtained. Inter- evaluator agreement was assessed using kappa test for agreement which ranged between a minimum of 0 and a maximum of 1. A final score (an average of the three evaluators' assessment) was computed. Patients were subdivided into three groups accordingly:

  • Group A: No change
  • Group B: Improvement up to 50%
  • Group C: Improvement more than 50%.


The major clinical changes following treatment included lightening of the color and/or reduction in the size of the darkened area [Figure 1]a and b and decrease in intensity of pigmentation and erythema and/or telangiectasia on dermoscopy [Figure 2]a and b [Table 1]. An average score of improvement (1.7) for all patients, compared to baseline 0.1 (approximately 0) was statistically significant (P= < 0.001). According to this score, 6 (17.1%) patients showed no change (group A); 19 (54.3%) patients showed up to 50% improvement (group B); and 10 (28.6%) patients showed >50% improvement (group C). Interestingly, all six patients with skin phototype III showed improvement; marked in four and moderate in two. We may therefore presume that periorbital darkening in fair skinned individuals is more favorably responsive to oxygen therapy.
Figure 1: (a) Two periorbital darkening patients showing improvement in the degree of pigmentation (before treatment to the left and after treatment with oxygen therapy to the right).
(b) Improvement of skin texture is noticeable, wrinkles have thinned and become less apparent


Click here to view
Figure 2: (a) Dermoscopic photographs before and after treatment of two patients showing improvement of erythema and telangiectasia. (b) Dermoscopic photographs before and after treatment of a patient showing decrease in the degree of pigmentation


Click here to view
Table 1: Post-treatment clinical and dermoscopic changes assessed by two evaluators


Click here to view


Pre-treatment dermoscopic evaluation of patients revealed that 33 (94.3%) of patients showed erythema and 26 (74.3%) patients showed telangiectasia. Post-treatment evaluation showed that improvement of erythema and telangiectasia took place in 22 (66.7%) and 15 (57.7%) patients, respectively. Oxygen significantly improves tissue oxygenation despite vasoconstriction. [3] This could explain improvement of patients through affection of the vascular component of periorbital darkening.

Healing of stasis ulcers, with regeneration of peri-ulcer skin following intra-ulcer application of hemoglobin and inhaled normobaric oxygen has been previously reported. [4] This was attributed to the anti-inflammatory effect of oxygen, [4] and promotion of oxygen-dependent collagen matrix formation. [5] This might explain the overall improvement of our patients, along with improvement of skin texture ([Figure 1]b). All patients received no treatment except for normobaric oxygen, 4 weeks prior to the study indicating that the changes observed may perhaps be attributable to normobaric oxygen. Lack of a control arm is a major limitation of this study.

 
  References Top

1.
Moody MN, Landau JM, Goldberg LH, Friedman PM. Fractionated 1550-nm Hyperpigmentation. Dermatol Surg 2012;38:139-42.  Back to cited text no. 1
    
2.
Zoheir WM, Kadry D, Mohamed EF. Clinical and dermoscopic evaluation of patients with periorbital darkening. J Egypt Women Dermatol Soc [In Press].  Back to cited text no. 2
    
3.
Striban A, Lentrodt S, Nandrean S, Pop A, Tschoepe D, Scherbaum WA. Functional changes in microcirculation during hyperbaric and normobaric oxygen therapy. Undersea Hyperb Med 2009;36:381-90.  Back to cited text no. 3
    
4.
Barnikol WK, Potzschke H. Complete healing of chronic wounds of a lower leg with hemoglobin spray and regeneration of an accompanying severe dermatoliposclerosis with intermittent normobaric oxygen inhalation (INBOI): A case report. Ger Med Sci 2011;9:Doc08.  Back to cited text no. 4
    
5.
Hutton JJ Jr, Tappel AL, Udenfriend S. Cofactor and substrate requirements of collagen proline hydroxylase. Arch Biochem Biophys 1967;118:231-40.  Back to cited text no. 5
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow